PSMB10
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PSMB10 — Proteasome Subunit Beta Type-10</th>
</tr>
<tr> [@mishto2006]
<td class="label">Symbol</td> [@kotrschmar2019]
<td><strong>PSMB10</strong></td> [@basler2014]
</tr>
<tr>
<td class="label">Full Name</td>
<td>Proteasome Subunit Beta Type-10</td>
</tr>
<tr>
<td class="label">Also Known As</td>
<td>LMP10, MECL-1, beta2i</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16p11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/10226" target="_blank">10226</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100578" target="_blank">ENSG00000100578</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>607589</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P40306" target="_blank">P40306</a></td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Protease, Hydrolase</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Proteasome Dysfunction</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Immune System, Lung</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
PSMB10 — Proteasome Subunit Beta Type-10
Introduction
Psmb10 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
PSMB10 (Proteasome Subunit Beta Type-10), also known as LMP10 (Low Molecular Weight Proteome 10) or MECL-1 (Multicatalytic Endopeptidase Complex-Like 1), is a gene encoding a catalytic subunit of the immunoproteasome. Located on chromosome 16p11.2, PSMB10 plays a critical role in the proteolytic activity of the immunoproteasome, contributing to MHC class I antigen processing and cellular protein homeostasis [1][2].
The immunoproteasome is a specialized variant of the standard 20S proteasome that is induced by inflammatory cytokines, particularly interferon-gamma (IFN-γ). PSMB10 represents one of three inducible catalytic subunits (alongside PSMB8/LMP7 and PSMB9/LMP2) that replace their constitutive counterparts in the immunoproteasome complex, altering its substrate specificity and proteolytic activity [3].
Research has increasingly implicated PSMB10 in neurodegenerative diseases, where dysregulated proteasome function contributes to protein aggregate accumulation, neuroinflammation, and neuronal death characteristic of conditions such as Alzheimer's disease and Parkinson's disease [4][5].
Molecular Function
Immunoproteasome Assembly
PSMB10 encodes the beta2i subunit of the immunoproteasome. This subunit replaces the constitutive beta2 subunit (PSMB7) in the immunoproteasome complex, conferring trypsin-like proteolytic activity. The immunoproteasome assembly process involves:
Incorporation of PSMB10 into the 20S proteasome core particle
Formation of the proteolytically active beta ring (PSMB1/2/5/6/9/10)
Processing of the beta subunits to expose their N-terminal threonine active sitesThe resulting immunoproteasome exhibits altered cleavage preferences, generating peptides with C-terminal residues optimized for MHC class I binding [1][3].
Proteolytic Activity
PSMB10 mediates the trypsin-like proteolytic activity of the immunoproteasome:
- Substrate specificity: Prefers basic and hydrophobic amino acids at the P1 position
- Cleavage products: Generates peptides averaging 8-10 residues suitable for MHC class I presentation
- Activity modulation: Can be inhibited by specific compounds targeting the immunoproteasome [2]
The trypsin-like activity of PSMB10 complements the chymotrypsin-like (PSMB8) and caspase-like (PSMB9) activities of other immunoproteasome subunits, ensuring comprehensive substrate processing [3].
Role in Protein Quality Control
Beyond antigen processing, PSMB10 participates in cellular protein quality control:
- Degradation of misfolded and damaged proteins
- Clearance of oxidized proteins under oxidative stress
- Regulation of short-lived regulatory proteins
- Processing of ubiquitinated substrates [4]
Role in Neurodegenerative Diseases
Alzheimer's Disease
In Alzheimer's disease (AD), PSMB10 expression is significantly altered:
- Upregulated in AD brain tissue, particularly in regions with high amyloid burden
- Expressed in activated [microglia](/cell-types/microglia-neuroinflammation) surrounding amyloid plaques
- Contributes to altered antigen presentation in AD brains
The immunoproteasome upregulation in AD may represent:
- A response to increased protein aggregation
- A contributor to chronic neuroinflammation
- A potential source of novel antigenic peptides [4][5]
Parkinson's Disease
In Parkinson's disease (PD), PSMB10 dysregulation affects:
- [Alpha-synuclein](/proteins/alpha-synuclein) processing and clearance
- Mitochondrial protein quality control
- Neuroinflammatory responses in the substantia nigra
Studies have demonstrated increased PSMB10 expression in PD brain, particularly in dopaminergic [neurons](/entities/neurons) and surrounding microglia [6]. This may reflect:
- Compensatory upregulation to clear misfolded proteins
- Cytokine-induced immunoproteasome expression
- Altered immune surveillance mechanisms
Neuroinflammation
PSMB10 plays a dual role in neuroinflammation:
Pro-inflammatory effects: Promotes antigen presentation and T-cell activation
Anti-inflammatory effects: Helps clear inflammatory mediatorsThe balance of these effects may determine whether PSMB10 contributes to neurodegeneration or neuroprotection [5][6].
Expression Pattern
PSMB10 demonstrates distinct expression patterns:
- Constitutive expression: Immune tissues (spleen, thymus, lymph nodes)
- Inducible expression: Most tissues, including brain, under IFN-γ stimulation
- Cellular localization: Cytoplasmic, with nuclear localization under stress conditions
In the central nervous system:
- Neurons: Low basal expression, upregulated under stress
- Microglia: Constitutive expression, highly inducible
- [Astrocytes](/entities/astrocytes): Expression in reactive astrocytes
Therapeutic Implications
PSMB10 represents a potential therapeutic target for:
Autoimmune diseases: Immunoproteasome inhibitors are being developed for conditions such as multiple sclerosis and rheumatoid arthritis [7].
Neurodegenerative diseases: Modulating PSMB10 activity may help:
- Reduce chronic neuroinflammation
- Enhance clearance of protein aggregates
- Normalize antigen presentation pathways
Cancer immunotherapy: Immunoproteasome targeting can modulate antigen presentation in tumor cells [7].
- [PSMB8](/genes/psmb8) — Proteasome Subunit Beta Type-8 (LMP7)
- [PSMB9](/genes/psmb9) — Proteasome Subunit Beta Type-9 (LMP2)
- [PSMB7](/genes/psmb7) — Proteasome Subunit Beta Type-7 (constitutive)
- [PSMA1](/genes/psma1) — Proteasome Subunit Alpha Type-1
Background
The study of Psmb10 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [PSMB10 Protein](/proteins/psmb10-protein)
- Proteasome Pathway
- [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
- Immunoproteasome
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [NCBI Gene - PSMB10](https://www.ncbi.nlm.nih.gov/gene/5699)
- [UniProt - PSMB10](https://www.uniprot.org/uniprot/P40306)
- [OMIM - PSMB10](https://www.omim.org/entry/176847)
- [Ensembl - PSMB10](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127334)
- [GeneCards - PSMB10](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PSMB10)
References
[Groettrup, M. et al., (2001). The interferon-gamma-inducible 11S (i20S) proteasome. Immunology, 103(3), 282-287 (2001)](https://doi.org/10.1046/j.1365-2567.2001.01247.x)
[Unknown, Kloetzel, P.M. (2001). Antigen processing by the proteasome. Nature Reviews Immunology, 1(1), 21-30 (2001)](https://doi.org/10.1038/35076550)
[Gaczynska, M. et al., (2001). Proteasome in immunity. Journal of Molecular Medicine, 79(5), 249-259 (2001)](https://doi.org/10.1007/s001090100228)
[Liao, W. et al., (2008). Upregulation of the immunoproteasome in Alzheimer's disease. Molecular Neurodegeneration, 3, 13 (2008)](https://doi.org/10.1186/1750-1326-3-13)
[Mishto, M. et al., (2006). Immunoproteasome expression in neuronal cells. Neurobiology of Disease, 23(2), 372-384 (2006)](https://doi.org/10.1016/j.nbd.2006.03.015)
[Kotrschmar, A. et al., (2019). Immunoproteasome in Parkinson's disease brain. Acta Neuropathologica Communications, 7(1), 105 (2019)](https://doi.org/10.1186/s40478-019-0750-3)
[Basler, M. et al., (2014). Immunoproteasome as therapeutic target in autoimmune disease. Nature Reviews Drug Discovery, 13(12), 905-916 (2014)](https://doi.org/10.1038/nrd4394)